CORT Relative Valuation
CORT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CORT is overvalued; if below, it's undervalued.
Historical Valuation
Corcept Therapeutics Inc (CORT) is now in the Overvalued zone, suggesting that its current forward PE ratio of 48.31 is considered Overvalued compared with the five-year average of 28.10. The fair price of Corcept Therapeutics Inc (CORT) is between 35.45 to 52.90 according to relative valuation methord. Compared to the current price of 71.20 USD , Corcept Therapeutics Inc is Overvalued By 34.59%.
Relative Value
Fair Zone
35.45-52.90
Current Price：71.20
34.59%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
11.34
P/B
Median3y
6.75
Median5y
6.10
2.29
FCF Yield
Median3y
4.22
Median5y
5.22
Competitors Valuation Multiple
The average P/S ratio for CORT's competitors is 47.80, providing a benchmark for relative valuation. Corcept Therapeutics Inc Corp (CORT) exhibits a P/S ratio of 7.95, which is -83.37% above the industry average. Given its robust revenue growth of 7.09%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Corcept Therapeutics Inc (CORT) currently overvalued or undervalued?
What is Corcept Therapeutics Inc (CORT) fair value?
How does CORT's valuation metrics compare to the industry average?
What is the current P/B ratio for Corcept Therapeutics Inc (CORT) as of Jul 19 2025?
What is the current FCF Yield for Corcept Therapeutics Inc (CORT) as of Jul 19 2025?
What is the current Forward P/E ratio for Corcept Therapeutics Inc (CORT) as of Jul 19 2025?